Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating Older Patients With Acute Myeloid Leukemia

This study has been completed.

Study NCT00003190 Information provided by Cancer and Leukemia Group B

First Received: November 1, 1999 Last Updated: June 21, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	April 2009
Primary Completion Date:	October 2008 (Final data collection date for primary outcome measure)

Publications:

Baer MR, George SL, Caligiuri MA, Sanford BL, Bothun SM, Mrózek K, Kolitz JE, Powell BL, Moore JO, Stone RM, Anastasi J, Bloomfield CD, Larson RA. Low-Dose Interleukin-2 Immunotherapy Does Not Improve Outcome of Patients Age 60 Years and Older With Acute Myeloid Leukemia in First Complete Remission: Cancer and Leukemia Group B Study 9720. J Clin Oncol. 2008 Jun 30; [Epub ahead of print]

Baer MR, George SL, Sanford BL, et al.: Cytarabine, daunorubicin and etoposide (ADE) chemotherapy in acute myeloid leukemia (AML) patients 60 years (CALGB 9720). [Abstract] Blood 110 (11): A-296, 2007.

Baer MR, George SL, Caligiuri MA, et al.: Phase III study of immunotherapy with recombinant interleukin-2 (IL-2) versus no further therapy in acute myeloid leukemia (AML) patients ≥ 60 years in first complete remission (CALGB 9720). [Abstract] Blood 108 (11): A-424, 2006.

Baer MR, George SL, Dodge RK, O'Loughlin KL, Minderman H, Caligiuri MA, Anastasi J, Powell BL, Kolitz JE, Schiffer CA, Bloomfield CD, Larson RA. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood. 2002 Aug 15;100(4):1224-32.